OverviewSuggest Edit

AlloVir (formerly ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. It focuses on the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients.

TypePublic
Founded2013
HQHouston, TX, US
Websiteallovir.com

Latest Updates

Employees (est.) (Jul 2020)21
Job Openings14
Revenue (FY, 2020)$0(-100%)
Share Price (Nov 2021)$22.3(-5%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at AlloVir

Ann Leen

Ann Leen

Chief Scientific Officer
Agustin Melian

Agustin Melian

Chief Medical Officer & Head of Global Medical Sciences
Edward Miller

Edward Miller

General Counsel
Jeroen van Beek

Jeroen van Beek

Chief Commercial Officer
Ercem Atillasoy

Ercem Atillasoy

Chief Regulatory and Safety Officer
Vikas Sinha

Vikas Sinha

President and Chief Financial Officer, Director
Show more

AlloVir Office Locations

AlloVir has offices in Houston, Cambridge, Waltham and Milano
Houston, TX, US (HQ)
2925 Richmond Ave
Cambridge, MA, US
139 Main St #500
Waltham, MA, US
200 Smith St #301
Milano, IT
Via Melchiorre Gioia, 8
Show all (4)

AlloVir Financials and Metrics

AlloVir Revenue

USD

Revenue growth (FY, 2019 - FY, 2020), %

(100%)

Net income (FY, 2020)

(69.8m)

EBIT (FY, 2020)

(71.3m)

Market capitalization (12-Nov-2021)

1.5b

Closing stock price (12-Nov-2021)

22.3

Cash (31-Dec-2020)

122.7m

EV

1.4b
AlloVir's current market capitalization is $1.5 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

1.1m165.0k

Revenue growth, %

(85%)(100%)

General and administrative expense

3.0m10.6m21.6m

R&D expense

1.7m16.2m49.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

165.0k

General and administrative expense

1.8m3.2m2.8m3.0m3.3m6.7m

R&D expense

1.2m2.8m5.7m6.8m8.9m17.2m

Operating expense total

2.9m5.9m8.5m9.8m12.2m23.9m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

22.2m61.1m122.7m

Prepaid Expenses

51.0k676.0k4.5m

Current Assets

25.3m127.3m361.3m

PP&E

350.0k812.0k
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020

Cash

64.4m78.3m142.3m

Prepaid Expenses

960.0k2.4m4.9m

Current Assets

117.4m107.3m383.9m

PP&E

332.0k313.0k295.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

2.4m(23.8m)(69.8m)

Depreciation and Amortization

19.0k73.0k

Accounts Payable

601.0k4.9m2.7m

Cash From Operating Activities

1.9m(20.2m)(60.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(2.5m)(7.8m)(15.1m)(9.3m)(21.0m)(44.6m)(30.9m)

Depreciation and Amortization

18.0k37.0k55.0k18.0k

Accounts Payable

836.0k2.0m3.0m(1.5m)(271.0k)4.3m1.7m

Cash From Operating Activities

(2.0m)(4.9m)(11.3m)(10.5m)(21.7m)(39.7m)(18.9m)
USDFY, 2018

Financial Leverage

-0.8 x
Show all financial metrics

AlloVir Operating Metrics

Jul, 2020

Patents (Foreign)

30

Patents (US)

2

Patents Pending

19

Product Candidates

5
Show all operating metrics

AlloVir Acquisitions / Subsidiaries

Company NameDateDeal Size
AlloVir International Designated Activity Company
AlloVir Italia S.R.L.
AlloVir Securities Corporation

AlloVir Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

AlloVir Online and Social Media Presence

Embed Graph

AlloVir News and Updates

AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET.

AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company’s lead product candidate, Viralym-M (ALVR105), an allogeneic, off-the-shelf, multi-virus specific investigational …

AlloVir Reports Third Quarter 2020 Financial Results

- Completed initial public offering raising $317.7M in gross proceeds

AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62nd Americ…

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients

- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients

AlloVir Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020.
Show more

AlloVir Blogs

AlloVir Appoints Ugo Capolino Perlingieri Head of Europe and Middle East Operations

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that Ugo Capolino Perlingieri has been appointed to the newly created position of General Manager of Europe and Middle East operations. In this role, he will be responsible for implementing clinical and commercial progr…

European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced it has been granted Orphan Drug Designation from the European Medicines Agency (EMA) for Viralym-M (ALVR105) as a potential treatment of viral diseases and infections in patients undergoing hematopoietic stem…

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, th…

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Research published in the journal BLOOD ADVANCES established the feasibility of using a small bank of third-party cell lines generated from carefully chosen donors to provide virus-specific T-cell therapy to a large number of patients. The data show coverage of more than 95 percent of patients w…

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation

AlloVir, a late-clinical stage allogeneic T-cell therapy company, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for Viralym-M (ALVR105), its lead allogeneic, off-the-shelf, multi-virus specific T-ce…

AlloVir Frequently Asked Questions

  • When was AlloVir founded?

    AlloVir was founded in 2013.

  • Who are AlloVir key executives?

    AlloVir's key executives are Ann Leen, Agustin Melian and Edward Miller.

  • How many employees does AlloVir have?

    AlloVir has 21 employees.

  • Who are AlloVir competitors?

    Competitors of AlloVir include Fate Therapeutics, Neurocrine Biosciences and Adaptive Biotechnologies.

  • Where is AlloVir headquarters?

    AlloVir headquarters is located at 2925 Richmond Ave, Houston.

  • Where are AlloVir offices?

    AlloVir has offices in Houston, Cambridge, Waltham and Milano.

  • How many offices does AlloVir have?

    AlloVir has 4 offices.